For the quarter ending 2025-09-30, TMCI had -$366K decrease in cash & cash equivalents over the period. -$11,901K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -16,288 | -33,320 |
| Depreciation and amortization expense | 2,778 | 5,037 |
| Provision for allowance for credit losses | -69 | 581 |
| Share-based compensation expense | 7,998 | 18,270 |
| Non-cash lease expense | 556 | 1,133 |
| Amortization of debt issuance costs | 75 | 148 |
| Amortization (accretion) of premium (discount) on marketable securities, net | 5 | 114 |
| Other, net | -531 | -219 |
| Accounts receivable | 2,557 | -9,985 |
| Inventory | -973 | 3,142 |
| Prepaid expenses and other assets | 615 | -84 |
| Other non-current assets | -62 | 365 |
| Operating lease liabilities | -829 | -1,553 |
| Accounts payable | -3,856 | 9,437 |
| Accrued liabilities | 2,118 | -5,309 |
| Other, net | -36 | -57 |
| Net cash provided by (used in) operating activities | -9,092 | 1,148 |
| Purchases of available-for-sale marketable securities | 4,640 | 30,249 |
| Sales and maturities of available-for-sale marketable securities | 16,185 | 33,408 |
| Purchases of property and equipment | 2,809 | 8,310 |
| Net cash provided by (used in) investing activities | 8,736 | -5,151 |
| Proceeds from insurance premium financing | 570 | 983 |
| Payments on insurance premium financing | 409 | 98 |
| Proceeds from exercise of employee stock options | 241 | 235 |
| Taxes from withheld shares | 412 | 415 |
| Net cash provided by (used in) financing activities | -10 | 705 |
| Net increase (decrease) in cash and cash equivalents | -366 | -3,298 |
| Cash and cash equivalents at beginning of period | 11,350 | - |
| Cash and cash equivalents at end of period | 7,686 | - |
TREACE MEDICAL CONCEPTS, INC. (TMCI)
TREACE MEDICAL CONCEPTS, INC. (TMCI)